No adverse reactions occurred in greater than 5% of people receiving<unk> . The most common adverse reactions occurring in > 2% of people receiving<unk>  in the pooled phase-III clinical trials were: * Diarrhea * Nausea * Rash
Ceftaroline fosamil
Imipenem
Amikacin
Imipenem/cilastatin/relebactam
Rifampicin
Secnidazole
Doxycycline
Doripenem